Induction of c- fos transcripts in early postimplantation mouse embryos by tgf-α, EGF, PDGF, and FGF.
- Published in:
- Molecular Reproduction & Development, 1991, v. 29, n. 3, p. 227, doi. 10.1002/mrd.1080290304
- By:
- Publication type:
- Article
Works matching AU Nielsen, Loretta L.
Results: 11
1
2
The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes in vitro and enhances their antitumor activity in vivo.
- Published in:
- 2000
- By:
- Publication type:
- journal article
3
Exenatide Augments First- and Second-Phase Insulin Secretion in Response to Intravenous Glucose in Subjects with Type 2 Diabetes.
- Published in:
- Journal of Clinical Endocrinology & Metabolism, 2005, v. 90, n. 11, p. 5991, doi. 10.1210/jc.2005-1093
- By:
- Publication type:
- Article
4
Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus.
- Published in:
- American Journal of Health-System Pharmacy, 2005, v. 62, n. 2, p. 173., doi. 10.1093/ajhp/62.2.173
- By:
- Publication type:
- Article
5
Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway.
- Published in:
- Oncogene, 2002, v. 21, n. 17, p. 2613, doi. 10.1038/sj.onc.1205353
- By:
- Publication type:
- Article
6
Patient characteristics, drug adherence patterns, and hypoglycemia costs for patients with type 2 diabetes mellitus newly initiated on exenatide or insulin glargine.
- Published in:
- 2009
- By:
- Publication type:
- journal article
7
Patient characteristics, drug adherence patterns, and hypoglycemia costs for patients with type 2 diabetes mellitus newly initiated on exenatide or insulin glargine.
- Published in:
- Current Medical Research & Opinion, 2009, v. 25, n. 3, p. 777, doi. 10.1185/03007990802715199
- By:
- Publication type:
- Article
8
Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years.
- Published in:
- 2008
- By:
- Publication type:
- journal article
9
Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years.
- Published in:
- Current Medical Research & Opinion, 2008, v. 24, n. 1, p. 275, doi. 10.1185/030079907X253870
- By:
- Publication type:
- Article
10
Development and validation of sensitive assays to quantitate gene expression after p53 gene therapy and paclitaxel chemotherapy using in vivo dosing in tumor xenograft models.
- Published in:
- Cancer Gene Therapy, 2000, v. 7, n. 11, p. 1469, doi. 10.1038/sj.cgt.7700257
- By:
- Publication type:
- Article
11
Evaluation of endostatin antiangiogenesis gene therapy in vitro and in vivo.
- Published in:
- Cancer Gene Therapy, 2001, v. 8, n. 12, p. 982, doi. 10.1038/sj.cgt.7700396
- By:
- Publication type:
- Article